H.B. NO. ¹⁰⁹⁷ H.D. 1

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

| 1 | SECTION 1. | Section 329-14, Hawaii Revised Statutes, is |
|----|-----------------|---|
| 2 | amended as foll | ows: |
| 3 | 1. By ame | nding subsection (b) to read as follows: |
| 4 | "(b) Any | of the following opiates, including their |
| 5 | isomers, esters | , ethers, salts, and salts of isomers, esters, |
| 6 | and ethers, unl | ess specifically excepted, whenever the existence |
| 7 | of these isomer | s, esters, ethers, and salts is possible within |
| 8 | the specific ch | emical designation: |
| 9 | (1) Acety | l-alpha-methylfentanyl (N-[1-(1-methyl-2- |
| 10 | phene | thyl)-4-piperidinyl]-N-phenylacetamide); |
| 11 | (2) Acety | <pre>lmethadol;</pre> |
| 12 | (3) Acety | l fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 13 | pheny | lacetamide), its optical, positional, and |
| 14 | geome | tric isomers, salts, and salts of isomers; |
| 15 | (4) Acryl | fentanyl [N-(1-phenethylpiperidin-4-yl)-N- |
| 16 | pheny | <pre>lacrylamide] (Other name: acryloylfentanyl);</pre> |

2023-1400 HB1097 HD1 HMS0

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (5) | AH-7921 (3,4-dichloro-N-[(1- |
|----|------|---|
| 2 | | <pre>dimethylamino)cyclohexylmethyl]benzamide);</pre> |
| 3 | (6) | Allylprodine; |
| 4 | (7) | Alphacetylmethadol (except levo-alphacetylmethadol, |
| 5 | | <pre>levomethadyl acetate, or LAAM);</pre> |
| 6 | (8) | Alphameprodine; |
| 7 | (9) | Alphamethadol; |
| 8 | (10) | Alpha-methylfentanyl (N-[1-(alpha-methyl-beta- |
| 9 | | phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl- |
| 10 | | 2-phenylethyl)-4-(N-propanilido)piperidine); |
| 11 | (11) | Alpha-methylthiofentanyl (N-[1-methyl-2-(2- |
| 12 | | <pre>thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);</pre> |
| 13 | (12) | Benzethidine; |
| 14 | (13) | Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N- |
| 15 | | phenylpropanamide), its optical isomers, salts, and |
| 16 | | salts of isomers; |
| 17 | (14) | Betacetylmethadol; |
| 18 | (15) | Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- |
| 19 | | <pre>piperidinyl]-N-phenylpropanamide);</pre> |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (16) | Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2- |
|----|------|--|
| 2 | | phenethyl)-3-methyl-4-piperidinyl]-N- |
| 3 | | phenylpropanamide); |
| 4 | (17) | Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen- |
| 5 | | 2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide); |
| 6 | (18) | Betameprodine; |
| 7 | (19) | Betamethadol; |
| 8 | (20) | Beta-methyl fentanyl (N-phenyl-N-(1-(2- |
| 9 | | phenylpropyl)piperidin-4-yl)propionamide) (Other name: |
| 10 | | <pre>[beta]-methyl fentanyl);</pre> |
| 11 | (21) | Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)- |
| 12 | | N,3-diphenylpropanamide) (Other names: [beta]'-phenyl |
| 13 | | <pre>fentanyl; 3-phenylpropanoyl fentanyl);</pre> |
| 14 | (22) | Betaprodine; |
| 15 | (23) | Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 16 | | <pre>phenylbutyramide);</pre> |
| 17 | (24) | Clonitazene; |
| 18 | (25) | Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 19 | | <pre>phenylcyclopropanecarboxamide);</pre> |
| 20 | (26) | Dextromoramide; |
| 21 | (27) | Diampromide; |

.

.

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (28) | Diethylthiambutene; |
|----|------|---|
| 2 | (29) | Difenoxin; |
| 3 | (30) | Dimenoxadol; |
| 4 | (31) | Dimepheptanol; |
| 5 | (32) | Dimethylthiambutene; |
| 6 | (33) | Dioxaphetyl butyrate; |
| 7 | (34) | Dipipanone; |
| 8 | (35) | Ethylmethylthiambutene; |
| 9 | (36) | Etonitazene; |
| 10 | (37) | Etoxeridine; |
| 11 | (38) | Fentanyl carbamate (ethyl (1-phenethylpiperidin-4- |
| 12 | | <pre>yl) (phenyl) carbamate);</pre> |
| 13 | (39) | 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-N-(1- |
| 14 | | phenethylpiperidin-4-yl)isobutyramide] (Other name: |
| 15 | | <pre>para-fluoroisobutyryl fentanyl);</pre> |
| 16 | (40) | 2'-fluoro ortho-fluorofentanyl (N-(1-(2- |
| 17 | | fluorophenethyl)piperidin-4-yl)-N-(2- |
| 18 | | fluorophenyl)propionamide) (Other name: 2'-fluoro 2- |
| 19 | | <pre>fluorofentanyl);</pre> |
| 20 | (41) | Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 21 | | phenylfuran-2-carboxamide); |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (42) | Furethidine; |
|----|------|--|
| 2 | (43) | Hydroxypethidine; |
| 3 | (44) | Ketobemidone; |
| 4 | (45) | Levomoramide; |
| 5 | (46) | Levophenacylmorphan; |
| 6 | (47) | Methoxyacetyl fentanyl (2-methoxy-N-(1- |
| 7 | | phenethylpiperidin-4-yl)-N-phenylacetamide); |
| 8 | (48) | 4'-methyl acetyl fentanyl (N-(1-(4- |
| 9 | | <pre>methylphenethyl)piperidin-4-yl)-N-phenylacetamide);</pre> |
| 10 | (49) | 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- |
| 11 | | <pre>piperidyl]-N-phenylpropanamide);</pre> |
| 12 | (50) | 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl- |
| 13 | | 4-piperidinyl]-N-phenylpropanamide); |
| 14 | (51) | Morpheridine; |
| 15 | (52) | MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); |
| 16 | (53) | Noracymethadol; |
| 17 | (54) | Norlevorphanol; |
| 18 | (55) | Normethadone; |
| 19 | (56) | Norpipanone; |
| 20 | (57) | Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1- |
| 21 | | <pre>phenethylpiperidin-4-yl)acetamide];</pre> |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (58) | Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1- |
|----|------|--|
| 2 | | <pre>phenethylpiperidin-4-yl)acrylamide);</pre> |
| 3 | (59) | Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1- |
| 4 | | phenethylpiperidin-4-yl)butyramide) (Other name: 2- |
| 5 | | <pre>fluorobutyryl fentanyl);</pre> |
| 6 | (60) | Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1- |
| 7 | | phenethylpiperidin-4-yl)propionamide) (Other name: 2- |
| 8 | | <pre>fluorofentanyl);</pre> |
| 9 | (61) | Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N- |
| 10 | | (1-phenethylpiperidin-4-yl)isobutyramide); |
| 11 | (62) | Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1- |
| 12 | | phenethylpiperidin-4-yl)acetamide) (Other name: 2- |
| 13 | | <pre>methyl acetylfentanyl);</pre> |
| 14 | (63) | Ortho-methyl methoxyacetyl fentanyl (2-methoxy-N-(2- |
| 15 | | <pre>methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide)</pre> |
| 16 | | (Other name: 2-methyl methoxyacetyl fentanyl); |
| 17 | (64) | Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1- |
| 18 | | <pre>phenethylpiperidin-4-yl)butyramide);</pre> |
| 19 | (65) | Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- |
| 20 | | phenethyl)-4-piperidinyl] propanamide; |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (66) | Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1- |
|----|------|---|
| 2 | | <pre>phenethylpiperidin-4-yl)furan-2-carboxamide);</pre> |
| 3 | (67) | Para-methylfentanyl (N-(4-methylphenyl)-N(1- |
| 4 | | phenethylpiperidin-4-yl)propionamide) (Other name: 4- |
| 5 | | <pre>methylfentanyl);</pre> |
| 6 | (68) | <pre>PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);</pre> |
| 7 | (69) | Phenadoxone; |
| 8 | (70) | Phenampromide; |
| 9 | (71) | Phenomorphan; |
| 10 | (72) | Phenoperidine; |
| 11 | (73) | Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 12 | | phenylbenzamide) (Other name: benzoyl fentanyl); |
| 13 | (74) | Piritramide; |
| 14 | (75) | Proheptazine; |
| 15 | (76) | Properidine; |
| 16 | (77) | Propiram; |
| 17 | (78) | Racemoramide; |
| 18 | (79) | Thenylfentanyl (N-[1-(2-thienyl)methyl-4-piperidyl]-N- |
| 19 | | phenylpropanamide), its optical isomers, salts, and |
| 20 | | salts of isomers; |

-

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (80) | Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- |
|----|-----------|--|
| 2 | | <pre>piperidinyl]-propanamide);</pre> |
| 3 | (81) | Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- |
| 4 | | phenylthiophene-2-carboxamide) (Other names: 2- |
| 5 | | thiofuranyl fentanyl; thiophene fentanyl); |
| 6 | (82) | Tilidine; |
| 7 | (83) | Trimeperidine; [and] |
| 8 | (84) | U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]- |
| 9 | | N-methylbenzamide) [-]; and |
| 10 | (85) | 2-(ethylamino)-2-(3-methoxylphenyl)cyclohexan-1- |
| 11 | | one(methoxetamine, MXE), including its salts, isomers, |
| 12 | | and salts of isomers whenever the existence of such |
| 13 | | salts, isomers, and salts of isomers is possible |
| 14 | | within the specific chemical designation." |
| 15 | 2. | By amending subsection (e) to read as follows: |
| 16 | "(e) | Depressants. Unless specifically excepted, the |
| 17 | schedule | shall include any material, compound, mixture, or |
| 18 | preparati | on which contains any quantity of the substance: |
| 19 | (1) | Mecloqualone; |
| 20 | (2) | Methaqualone; |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (3) | Etizolam (including its optical, positional, and |
|----|------|---|
| 2 | | geometric isomers, salts, and salts of isomers, where |
| 3 | | possible); [or] |
| 4 | (4) | Flualprazolam (including its optical, positional, and |
| 5 | | geometric isomers, salts, and salts of isomers, where |
| 6 | | possible)[-]; |
| 7 | (5) | N-ethylhexedrone (Other names: |
| 8 | | aethylaminohexanophenone, 2-(ethylamino)-1- |
| 9 | | <pre>phenylhexan-s1-one);</pre> |
| 10 | (6) | alpha-pyrrolidinohexanophenone (Other names: a-PHP, |
| 11 | | apyrrolidinohexanophenone, 1-phenyl-2-(pyrrolidine-1- |
| 12 | | yl)hexan-1-one); |
| 13 | (7) | 4-methyl-alphaethylaminopentiophenone (Other names: |
| 14 | | 4-MEAP, 2-(ethylamino)-1-(4-methylphyl)pentan-1-one); |
| 15 | (8) | 4'-methyl-alphapyrrolidinohexiophenone (Other names: |
| 16 | | MPHP, 4'-methyl-alphapyrrolidinohexanophenone, 1-(4- |
| 17 | | <pre>methylphenyl)-2-(pyrrolidine-1-yl)hexan1-one);</pre> |
| 18 | (9) | Alpha-pyrrolidinoheptaphenone (Other names: PV8, 1- |
| 19 | | phenyl-2-(pyrrolidine-1-yl)heptan-1-one); and |
| 20 | (10) | 4'chloro-alphapyrrolidinovalerophenone (Other names: |
| 21 | | 4-chloro-a-PVP, 4'-chloro-apyrrolidinopentiophenone, |

2023-1400 HB1097 HD1 HMS0

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | | 1-(4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-one) |
|----|------------|--|
| 2 | | including their optical, positional, and geometric |
| 3 | | isomers, salts, and salts of isomers whenever the |
| 4 | | existence of such salts, isomers, and salts of isomers |
| 5 | | is possible within the specific chemical designation." |
| 6 | 3. I | By amending subsection (f) to read as follows: |
| 7 | "(f) | Stimulants. Unless specifically excepted or unless |
| 8 | listed in | another schedule, any material, compound, mixture, or |
| 9 | preparatio | on [which] <u>that</u> contains any quantity of the following |
| 10 | substances | s having a stimulant effect on the central nervous |
| 11 | system, in | ncluding its salts, isomers, and salts of isomers: |
| 12 | (1) | Aminorex; |
| 13 | (2) | Cathinone; |
| 14 | (3) | 4,4'-dimethylaminorex (common name: 4,4'-DMAR); |
| 15 | (4) | Fenethylline; |
| 16 | (5) | Methcathinone; |
| 17 | (6) | 4-methylaminorex; |
| 18 | (7) | N-ethylamphetamine; |
| 19 | (8) | N,N-dimethylamphetamine; |
| 20 | (9) | Substituted cathinones, any compound, except bupropion |
| 21 | | or compounds listed under a different schedule, |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | | structurally derived from 2-aminopropan-1-one by |
|----|-----|--|
| 2 | | substitution at the 1-position with either phenyl, |
| 3 | | naphthyl, or thiophene ring systems, whether or not |
| 4 | | the compound is further modified in any of the |
| 5 | | following ways: |
| 6 | (A) | By substitution in the ring system to any extent with |
| 7 | | alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or |
| 8 | | halide substituents, whether or not further |
| 9 | | substituted in the ring system by one or more other |
| 10 | | univalent substituents; |
| 11 | (B) | By substitution at the 3-position with an acyclic |
| 12 | | alkyl substituent; or |
| 13 | (C) | By substitution at the 2-amino nitrogen atom with |
| 14 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by |
| 15 | | inclusion of the 2-amino nitrogen atom in a cyclic |
| 16 | | structure. |
| 17 | | Some other trade names: Mephedrone (2-methylamino-1- |
| 18 | | p-tolylpropan-1-one), also known as 4- |
| 19 | | methylmethcathinone (4-MMC), methylephedrone or MMCAT; |
| 20 | | Methylenedioxypyrovalerone (MDPV, MDPK); methylone or |
| 21 | | 3,4-methylenedioxymethcathinone; and 1- |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | | (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, |
|----|------|---|
| 2 | | monohydrochloride, also known as Ethylone, bk-MDEA |
| 3 | | hydrochloride, MDEC; 3,4-Methylenedioxy-N- |
| 4 | | ethylcathinone; bk-Methylenedioxyethylamphetamine, 4- |
| 5 | | <pre>methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-</pre> |
| 6 | | pyrrolidinopropiophenone (4-MePPP); alpha- |
| 7 | | pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3- |
| 8 | | benzodioxol-5-yl)-2-(methylamino)butan-1-one |
| 9 | | (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan- |
| 10 | | 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2- |
| 11 | | (methylamino)pentan-1-one (pentylone, bk-MBDP); 4- |
| 12 | | fluoro-N-methylcathinone (4-FMC, flephedrone); 3- |
| 13 | | <pre>fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-</pre> |
| 14 | | 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha- |
| 15 | | pyrrolidinobutiophenone ([alpha]-PBP) and their |
| 16 | | optical, positional, and geometric isomers, salts and |
| 17 | | salts of isomers, whenever the existence of such |
| 18 | | salts, isomers, and salts of isomers is possible; and |
| 19 | (10) | 1-(4-methoxyphenyl)-N-methylpropan-2-amine (Other |
| 20 | | names: para-methoxymethamphetamine; PMMA)[-]; |

2023-1400 HB1097 HD1 HMS0



| 1 | (11) | Ethyl 2-(1-(5-fluoropentyl)-1Hindazole-3-carboxamido)- |
|----|-----------|--|
| 2 | | 3,3-demethylbutanoate (Other name: 5FEDMB-PINACA); |
| 3 | (12) | Methyl 2-(1-(5-fluropentyl)-1Hindole-3-carboxamido)- |
| 4 | | 3,3-dimethylbutanoate (Other names: 5FMDMB-PICA; 5F- |
| 5 | | MDMB-2201); |
| 6 | (13) | <u>N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-</u> |
| 7 | | carboxamide (Other names: FUB-AKB48; FUB-APINACA; |
| 8 | | AKB48 N-(4-fluorobenzyl)); |
| 9 | (14) | <u>1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-</u> |
| 10 | | indazole-3-carboxamide (Other names: 5F-CUMYLPINACA; |
| 11 | | SGT-25); and |
| 12 | (15) | (1-(4-Fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- |
| 13 | | tetramethylcyclopropyl)methanone (Other name: FUB- |
| 14 | | 144) including their salts, isomers, and salts of |
| 15 | | isomers whenever the existence of such salts, isomers, |
| 16 | | and salts of isomers is possible within the specific |
| 17 | | chemical designation." |
| 18 | SECT | ION 2. Section 329-20, Hawaii Revised Statutes, is |
| 19 | amended b | y amending subsection (d) to read as follows: |
| 20 | "(d) | Stimulants. Unless listed in another schedule, any |
| 21 | material, | compound, mixture, or preparation [which] <u>that</u> |

2023-1400 HB1097 HD1 HMSO

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | contains | any quantity of the following substances having a |
|----|-----------|---|
| 2 | stimulant | effect on the central nervous system, including its |
| 3 | salts, is | omers, and salts of isomers whenever the existence of |
| 4 | such salt | s, isomers, and salts of isomers is possible within the |
| 5 | specific | chemical designation: |
| 6 | (1) | Cathine ((+)-norpseudoephedrine); |
| 7 | (2) | Diethylpropion; |
| 8 | (3) | Fencamfamin; |
| 9 | (4) | Fenproporex; |
| 10 | (5) | Lorcaserin; |
| 11 | (6) | Mazindol; |
| 12 | (7) | Mefenorex; |
| 13 | (8) | Modafinil; |
| 14 | (9) | Pemoline (including organometallic complexes and |
| 15 | | chelates thereof); |
| 16 | (10) | Phentermine; |
| 17 | (11) | Pipradrol; |
| 18 | (12) | Serdexmethylphenidate; |
| 19 | (13) | Sibutramine; |
| 20 | (14) | Solriamfetol; [and] |

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (15) | SPA (1-dimethylamino-1,2-dephenylethane, |
|----|-----------|---|
| 2 | | lefetamine)[-]; |
| 3 | (16) | Serdexmethylphenidate, including its salts, isomers, |
| 4 | | and salts of isomers; and |
| 5 | (17) | Daridorexant and its salts." |
| 6 | SECT | ION 3. Section 329-22, Hawaii Revised Statutes, is |
| 7 | amended b | y amending subsection (d) to read as follows: |
| 8 | "(d) | Depressants. Unless specifically exempted or |
| 9 | excluded | or unless listed in another schedule, any material, |
| 10 | compound, | mixture, or preparation [which] <u>that</u> contains any |
| 11 | quantity | of the following substances having a depressant effect |
| 12 | on the ce | ntral nervous system, including its salts, isomers, and |
| 13 | salts of | isomers: |
| 14 | (1) | Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1- |
| 15 | | yl]butanamide) (Other names: BRV; UCB-34714; |
| 16 | | Briviact) and its salts; |
| 17 | (2) | Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy- |
| 18 | | <pre>propionamide], (Vimpat);</pre> |
| 19 | (3) | Lasmiditan (2,4,6-trifluoro-N-(6-(1-methylpiperidine- |
| 20 | | 4-carbonyl)pyridine-2-yl-benzamide); [and] |

2023-1400 HB1097 HD1 HMS0

.

H.B. NO. ¹⁰⁹⁷ H.D. 1

| 1 | (4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic |
|---|---|
| 2 | acid][-]; and |
| 3 | (5) Ganaxolone and its salts." |
| 4 | SECTION 5. Statutory material to be repealed is bracketed |
| 5 | and stricken. New statutory material is underscored. |
| 6 | SECTION 6. This Act shall take effect on June 30, 3000. |

H.B. NO. ¹⁰⁹⁷ H.D. 1

Report Title: Uniform Controlled Substances Act

Description:

Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329-11, Hawaii Revised Statutes. Effective 6/30/3000. (HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.